Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.
about
Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexesOptimizing the use of neoadjuvant endocrine therapy.Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patientsThe changing role of ER in endocrine resistance.The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromataseEstrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.Targeting PI3K/mTOR Signaling in Cancer.Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer.Horizontal Transfer of Tamoxifen Resistance in MCF-7 Cell Derivates: Proteome Study.Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition.
P2860
Q28306753-F3247110-BAAB-4212-9112-9A87222744A3Q33925038-CEF3C356-A7D1-457F-83F9-5469014C594AQ34022694-C9828241-5F85-4CFA-BF16-B69D41F5F5E2Q35088147-692FD229-0256-4884-8EB1-DB27B51E7726Q36336601-FDF22368-0689-4002-83E3-7D209D8F86E6Q37033301-80F4463E-E24D-4EB7-B71D-00329C21A9E2Q37565213-FC939B0F-8D62-4832-8ED5-E17B0ABBC100Q37674501-EBE997BA-8716-4043-8315-3EED1ACC2E05Q37688020-2FB6B394-F2B9-486E-A209-7595FE11C373Q37725655-8B15AB1C-1201-4C56-A623-3113268761E4Q38238598-4F5F6CF6-9A41-49F9-A802-A3FCF0CFA0B3Q38602947-6EA718B9-8F37-4B92-97AB-18BF27B5DC6EQ38933237-E980EA6B-1240-4A3C-B7E6-97CFDFDB317DQ47129780-7220D989-D93D-4D3E-B31B-DE72709E6D52Q47802521-88D74153-19DF-44B0-8A69-26D4CF718B1FQ55710176-FF2F103A-ABC8-4483-89FD-B08E97D0A1AC
P2860
Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.
@ast
Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.
@en
type
label
Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.
@ast
Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.
@en
prefLabel
Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.
@ast
Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.
@en
P2093
P2860
P356
P1476
Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.
@en
P2093
Carlos L Arteaga
Emily M Fox
Todd W Miller
P2860
P356
10.3389/FONC.2012.00145
P577
2012-10-16T00:00:00Z